source
- Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assetsServier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…Endpoints · 1mo ago↗ source
- STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drugThe French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.STAT · 1mo ago↗ source
- #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroupCHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Indiv…